title: Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results.
abstract: BACKGROUND
  Breast cancer is the second leading cancer causing death in women. Circulating tumor cells are among the prognostic factors while tumor markers are of diagnostic value and can be used for follow-up. The aim of this study was to investigate the correlation between the prognostic significance of the serum CA15-3 levels, number of circulating tumor cells and histopathological tumor factors.
  
  
  METHODS
  Thirty patients recently diagnosed with breast cancer were included in the study. Number of circulating tumor cells and serum CA15-3 level were assessed when metastasis was detected and diagnostic value was assessed. Presence of associations with estrogen and progesterone receptors, c-erbB2, Ki-67 proliferation index and histological grade were also evaluated.
  
  
  RESULTS
  Median overall survival of the patients with serum CA15-3 levels of >108 ng/dl was 19 months whereas for those with a low serum level it was 62 months. Median overall survival for CTC ≥5vs CTC<5 patients was 19 months and 40 months respectively. The difference between the two groups was statistically significant.
  
  
  CONCLUSIONS
  Prognostic significance of the CTC count and CA15-3 levels in metastatic breast cancer patients was demonstrated.
authors.affiliation: Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey.
authors.forename: Mustafa Oktay
authors.initials: MO
authors.lastname: Tarhan
authors.forename: Ataman
authors.initials: A
authors.lastname: Gonel
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Kucukzeybek
authors.forename: Cigdem
authors.initials: C
authors.lastname: Erten
authors.forename: Serap
authors.initials: S
authors.lastname: Cuhadar
authors.forename: Seyran Ceri
authors.initials: SC
authors.lastname: Yigit
authors.forename: Aysenur
authors.initials: A
authors.lastname: Atay
authors.forename: Isil
authors.initials: I
authors.lastname: Somali
authors.forename: Ahmet
authors.initials: A
authors.lastname: Dirican
authors.forename: Lutfiye
authors.initials: L
authors.lastname: Demir
authors.forename: Mehmet
authors.initials: M
authors.lastname: Koseoglu
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000097:blood / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D018396:Mucin-1